This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary IL-1 Therapeutic Antibody Development
Background of IL-1
IL-1 plays a crucial role in malignancies, impacting the tumor microenvironment and promoting the onset and progression of cancer. Considering the emerging significance of the IL-1 pathway in the treatment of various solid tumors in companion animals, BioVenic offers development services for veterinary IL-1 therapeutic antibodies. We provide comprehensive coverage from gene synthesis to antibody preparation, dedicated to advancing the field of companion animal cancer treatment.
Background of IL-1
| Full Name | Interleukin 1 |
|---|---|
| Target Profile | The IL-1 family ligands include seven agonistic molecules (IL-1α, IL-1β, IL-18, IL-33, IL-36α, β, and γ), three receptor antagonists (IL-1Ra, IL-36Ra, and IL-38), and the anti-inflammatory cytokine (IL-37). Primarily produced by activated macrophages, IL-1 can modulate the expression of IL-1 receptors on various cell types. As a prototypical primary inflammatory cytokine, IL-1 is downstream of microbial components, tissue damage, metabolic aberrations, and oncogene sensors. |
MoA of IL-1
The two main forms of IL-1, IL-1α and IL-1β, function by binding to the IL-1R, activating downstream signaling pathways, followed by dimerization of IL-1R1 with IL-1RAcP. This interaction can be competitively inhibited by IL-1RA and IL-38. Upon agonist binding, further involvement in signaling intermediaries occurs, subsequently activating transcription factors like NF-κB and mitogen-activated protein kinase (MAPK) pathways. The transcriptional upregulation of inflammatory genes may lead to pro-tumorigenic or anti-tumorigenic phenotypes.
Fig.1 Schematic diagram of IL-1β signaling functions in cancer.1
Application in Veterinary Therapeutics
Inflammation is a key characteristic of malignant phenotypes. IL-1 has been shown to be upregulated in many types of animal tumors. It can also be directly produced by cancer cells and act as a growth factor, enhancing the synthesis of other cytokines or chemokines. Protein comparison of cytokine IL-1 shows that the protein regions and domains are highly conserved among mammalian species. Using veterinary therapeutic antibodies targeting IL-1 inhibits its action, thereby reducing inflammation and modulating the immune signaling pathways affected by IL-1, which has the ability to be beneficial in cancer treatment.
Veterinary IL-1 Therapeutic Antibody Development Services
Considering the role of IL-1 overexpression in companion animal cancer development, BioVenic offers veterinary IL-1 therapeutic antibody development services, covering the entire process from initial antibody design to the final production and validation of the product. Specific antibodies targeting IL-1 are designed and synthesized according to specific needs, assisting in the development of antibodies with high affinity and specificity.
For more information about our veterinary IL-1 therapeutic antibody development services, please click the link below.
Why Choose Us?
BioVenic employs the latest biotechnologies and antibody engineering techniques, including hybridoma technology, single B cell, and phage display, ensuring that the developed antibodies have high specificity and activity.
Our product development process includes strict quality control measures and safety assessments to ensure that the antibodies are not only effective but also safe for animals.
Our antibody development service is not limited to one species; through species-specific antibody development, the IL-1 antibodies we help develop target various companion animals, such as canine, feline and equine, offering broad therapeutic applications.
IL-1 is related to inflammation in the tumor microenvironment and the proliferation and invasion of tumor cells, hence veterinary therapeutic antibodies targeting IL-1 show potential application value in certain cancer treatments. BioVenic offers veterinary IL-1 therapeutic antibody development services, assisting your projects in the field of companion animal cancer with full process coverage. If you have this need, please contact us now.
Reference
- Baker, Kevin J., et al. "IL-1 family members in cancer; two sides to every story." Frontiers in immunology 10 (2019): 1197.